Pericyazine
From Ganfyd
rINN: Pericyazine
Pharmacological Information
Pharmacology Images
Pericyazine in the:
BNF-registration required
BNF for children-registration required
Relevant Clinical Literature
Systematic reviews from Pubmed
Other Literature
Please read pharmacological data limitations
Contents |
Introduction
Clinical Use
Indications
Indication: schizophrenia (and other psychoses)
- Initially 75mg/day in divided doses (15-30mg/day in the elderly)
- Increased in weekly increments of 25mg
- Titrate dose according to response - max. dose 300mg/day
Indication: short-term treatment of anxiety, agitation, and violent behaviour
- Initially 15-30mg/day (5-10mg/day in the elderly)
- Taken in 2 divided doses - the larger dose in the evening
- Dose adjusted according to response
Class Clinical Issues
Contra-indications
Dementia is probably a contraindication for any antipsychotic (fair evidence for increased mortality in long term use) and has an interesting medicolegal potential as it is unclear if following recent changes in datasheets (SPCs) and warnings from the regulatory authorities (eg FDA) any manufacturer will share liability for out of licence use (off license) use in newly commenced patients. In the UK an urgent review is taking place as of 2008.
- CNS depression
- Phaeochromocytoma
Cautions
- Driving
- Breast feeding and pregnancy (many contra-indicated or best avoided)
- Withdrawal should be gradual
- Hepatic impairment
- Renal impairment
- Cardiovascular disease
- Parkinsonism
- Epilepsy
- Blood dyscrasias
- Depression
- Myasthenia gravis
- Associated with increased venous thromboembolic disease
Side-effects
- Postural hypotension
- Parkinsonism
- Dystonia
- Akathisia
- Tardive dyskinesia
- Jaundice
- Drowsiness
- Apathy
- Excitement
- Neuroleptic malignant syndrome
- Insomia
- Anticholinergic side-effects
- Blood dyscrasias
- Hyperprolactinaemia
- Weight gain
- Skin pigmentation (purple)
- Photosensitisation at higher doses
- Cataracts & corneal opacities
